Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies. - Wikidata - awgldk - TriplyDB

Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies.

Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies.

http://www.wikidata.org/entity/Q38516237

about

Ketoconazole-Associated Liver Injury in Drug-Drug Interaction Studies in Healthy Volunteers.Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.Pharmacokinetic interaction between the CYP3A4 inhibitor ketoconazole and the hormone drospirenone in combination with ethinylestradiol or estradiol Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A.Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.No Increased Risk of Ketoconazole Toxicity in Drug-Drug Interaction Studies.Pharmacokinetic Drug Interactions of Apatinib With Rifampin and Itraconazole.Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when co-administered with dual or selective CYP2C9 and CYP3A interacting drugs.

P2860

Q34511634-469A49F9-0557-4D4B-AB5F-30B329EEF495 Q34556733-27901AC0-C7D4-4886-B121-1E5FDC5FB700 Q36410060-1BDCCA46-F1B4-4598-AE4C-C47579EC28A0 Q38726643-D736E05B-B7A2-4447-AB07-9335CF62E3B7 Q38738090-5E2069F1-B818-41D1-ADB3-5781C22C0964 Q38894543-2B38BB7B-A86E-4BD7-8ABF-21D3F6FF843C Q47885966-63CC6170-8AEF-4CF1-8345-B8767B84409E Q48157676-73C4B546-4324-4B40-ACA1-498D4107FB2F Q48228832-36BAD300-303F-4C2B-B4DC-72BABF308499

P2860

Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies.

http://www.wikidata.org/entity/Q38516237

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Best practices for the use of ...... drug-drug interaction studies.

@en

type

label

Best practices for the use of ...... drug-drug interaction studies.

@en

prefLabel

Best practices for the use of ...... drug-drug interaction studies.

@en

P1433

Q38516237-035B4B40-F1FF-44E4-8CEF-8518359B3A1E

P1476

Q38516237-D1E38BFA-E835-40E0-A3F2-3EFB13A3BE05

P2093

Q38516237-0015452E-5C4C-4A77-ADF3-BBD36BB873D4

Q38516237-249C6D6F-BDC2-4B7B-B6D4-0C8C04E4C88C

Q38516237-3587D21D-507D-4EB0-9F58-929F5D7E1F9E

Q38516237-8117F25A-0FAB-4108-90EA-3D4EAEBC8A03

Q38516237-87C1040F-8583-4195-88C0-6D65CAEB57F9

Q38516237-BD5EA25E-1D78-48F7-A01E-566552C7DE0A

Q38516237-E1BE18B9-5A71-4CB0-B7D8-0630BE4B12E9

Q38516237-F850BC0D-B9DA-4A1E-8004-7A20AA0A6DC1

Q38516237-FDC23C10-EF11-4154-821E-BBB7CB053CC8

P2860

Q38516237-05BC3FD9-73FC-4EB2-BDF3-5E90502F8A37

Q38516237-14B2456C-E4A1-4444-8E9A-67B40F8ED995

Q38516237-17C3D999-96D6-4DC9-9BD7-E9F754476D4D

Q38516237-201B1431-62A8-49D1-A913-63764418F468

Q38516237-29DAE72E-3BF1-4E07-AFD8-CA75C2655606

Q38516237-34AD025A-6775-4957-9249-17121B8AA89B

Q38516237-3B06C7B1-4994-4A5A-841E-5169AA6E028E

Q38516237-4FBA198F-F0D2-4D23-8FAB-412F629C7615

Q38516237-5466831A-F8A1-4E0C-A093-F6976993E1A7

Q38516237-5C25BF9B-5F66-449F-874B-79A5FC69D0EE

P304

Q38516237-0ACEFAFD-4599-454A-8FD3-3E37CED44DDC

P31

Q38516237-06900667-5104-4442-87B2-38232E635AE0

P356

Q38516237-A48B80A1-A405-4476-A14F-42F60048D0EE

P433

Q38516237-7F02C218-0FD2-4A0C-8059-7CB5060CD8DE

P478

Q38516237-92E3534D-232F-4A80-B83C-A3EEB7B5E9FF

P577

Q38516237-9F53613F-73DF-4288-AB49-927C412B1908

P698

Q38516237-41CAB93C-CCC6-408F-B682-ED418611E7DC

P921

Q38516237-9525120D-652B-4440-B9BA-30E31712CD40

P356

P1433

The Journal of Clinical Pharmacology

P1476

Best practices for the use of ...... drug-drug interaction studies.

@en

P2093

Akintunde Bello

http://www.w3.org/2001/XMLSchema#string

Donald Heald

http://www.w3.org/2001/XMLSchema#string

Edward O'Mara

http://www.w3.org/2001/XMLSchema#string

Lichuan Liu

http://www.w3.org/2001/XMLSchema#string

Mark J Dresser

http://www.w3.org/2001/XMLSchema#string

Mark Rogge

http://www.w3.org/2001/XMLSchema#string

S Aubrey Stoch

http://www.w3.org/2001/XMLSchema#string

Sarah M Robertson

http://www.w3.org/2001/XMLSchema#string

Steven Ferenc Komjathy

http://www.w3.org/2001/XMLSchema#string

P2860

Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers

Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.

Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data.

Interaction of common azole antifungals with P glycoprotein

Role of itraconazole metabolites in CYP3A4 inhibition.

Hepatic safety of itraconazole.

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Pharmacokinetics of itraconazole following oral administration to normal volunteers.

Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 2C9 by ritonavir or nelfinavir.

Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin

P304

143-151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.562

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26044116

http://www.w3.org/2001/XMLSchema#string

P921